

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Jayex Healthcare Limited
ABN 15 119 122 477

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brian Renwick
Date of last notice	9 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	4 June 2018
No. of securities held prior to change	<u>Direct</u> 115,000 Fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	<u>Direct</u> 1,130,653 Fully paid ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price \$0.0199 (1.99 cents) per share

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	<u>Direct</u> 1,245,653 Fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares issued to Directors in lieu of outstanding Directors fees pursuant to Resolution 7 of the Company's Notice of Annual General Meeting as approved by shareholders on 25 May 2018

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Jayex Healthcare Limited
ABN	15 119 122 477

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Boyd
Date of last notice	13 April 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Michael Boyd has a relevant interest, in accordance with section 608(3)(b) of the Corporations Act 2001 (Cth), in the 74,981,855 securities held by Covenant Holdings (WA) Pty Ltd through his position as controlling Shareholder of that company. Michael Boyd has a relevant interest, in accordance with section 608(3)(b) of the Corporations Act 2001 (Cth), in the 335,169 securities held by New Medical Enterprises Pty Ltd through his position as controlling Shareholder of that company.
Date of change	4 June 2018
No. of securities held prior to change	<u>Covenant Holdings (WA) Pty Ltd</u> 74,981,855 fully paid ordinary shares <u>New Medical Enterprises Pty Ltd</u> 335,169 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Class	Fully paid ordinary shares
Number acquired	3,481,055
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price \$0.0199 (1.99 cents) per share
No. of securities held after change	<u>Covenant Holdings (WA) Pty Ltd</u> 78,462,910 fully paid ordinary shares <u>New Medical Enterprises Pty Ltd</u> 335,169 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares issued to Directors in lieu of outstanding Directors fees pursuant to Resolution 4 of the Company's Notice of Annual General Meeting held on 25 May 2018 as approved by shareholders.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Jayex Healthcare Limited
ABN	15 119 122 477

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Chan
Date of last notice	15 May 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	AMG Corporate Pty Ltd <The AMG Super Fund A/C> is the registered holder of the securities. Mr Chan is a Director and beneficiary of this entity.
Date of change	(a) 29 May 2018 (b) 4 June 2018
No. of securities held prior to change	<u>AMG Corporate Pty Ltd <The AMG Super Fund A/C></u> 300,000 Fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	(a) 44,685 (b) 1,005,025
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) \$0.019 (1.9 cents) per share (b) Deemed issue price of \$0.0199 (1.99 cents) per share

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	AMG Corporate Pty Ltd <The AMG Super Fund A/C> 1,349,710 Fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) On-market acquisition (b) Shares issued to Directors in lieu of outstanding Directors fees pursuant to Resolution 5 of the Company's Notice of Annual General Meeting as approved by shareholders on 25 May 2018

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.